Consistency of Extended-Release Niacin/Laropiprant Effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 Ratio Across Patient Subgroups

Extended-release niacin/laropiprant lipid-altering consistency across patient subgroups

(2011) H. Bays et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Inflammatory markers, lipoprotein components and risk of major cardiovascular events in 65,005 men and women in the Apolipoprotein MOrtality RISk study (AMORIS)

(2010) Ingar Holme et al.   ATHEROSCLEROSIS

Efficacy and safety of extended-release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia

(2010) S. Shah et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Efficacy and tolerability of extended-release niacin/laropiprant in dyslipidemic patients with metabolic syndrome

(2010) Harold E. Bays et al.   Journal of Clinical Lipidology

Flushing Profile of Extended-Release Niacin/Laropiprant Versus Gradually Titrated Niacin Extended-Release in Patients With Dyslipidemia With and Without Ischemic Cardiovascular Disease

(2009) Darbie Maccubbin et al.   AMERICAN JOURNAL OF CARDIOLOGY

Heart Disease and Stroke Statistics—2010 Update

(2009) et al.   CIRCULATION

Whatʼs the deal with niacin development: is laropiprant add-on therapy a winning strategy to beat a straight flush?

(2009) Harold E Bays et al.   CURRENT OPINION IN LIPIDOLOGY

Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia

(2008) D. Maccubbin et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Effects of Laropiprant on Nicotinic Acid-Induced Flushing in Patients With Dyslipidemia††A list of study investigators appears in the Appendix.

(2007) John F. Paolini et al.   AMERICAN JOURNAL OF CARDIOLOGY